“Global Cancer Immunotherapy market set to grow to $117bn by 2024” says new Visiongain report
21 January 2019
Visiongain has launched a new pharma report Global Cancer Immunotherapy Market Report : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics.
Immunotherapeutics and targeted therapies are emerging as promising treatment options for various cancer types. In the biological cancer drug category, monoclonal antibodies (mAbs) have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity.
The lead analyst of the report commented "The cancer immunotherapy market remains attractive, as it is a large and growing clinical area with growing incidence of cancer cases, globally. Significant unmet need exists in the cancer market due to the rising need for more compelling clinical evidences and improved patient convenience.
In addition, increased medical education to improve clinical practice, improved care coordination between therapies and sites of care, and enhanced decision tools and practice guidelines are expected to drive future trends and innovations."
Leading companies featured in the report include Adaxic Inc., AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Eli Lilly and Co., Medtronic Plc, Merck & Co., Inc. (Merck), Novartis, Pfizer, Roche
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.